| Neuro3d (Acquired by Evotec AG)
| Neuro3d SA is a biopharmaceutical company focused on discovery and development of innovative treatments for psychiatric disorders such as schizophrenia, depression or anxiety. Neuro3d has three compounds in clinical development; the atypical antipsychotic ocaperidone is in Phase II for schizophrenia and two antidepressants are in Phase I. Neuro3d was founded in November 2000 and is located in Mulhouse, France. More information on www.neuro3d.fr | |
• Show past press releases
• Edit this company
| ELEVATOR PITCH |  | |
Neuro3d is a drug development company combining drug development for new M of A with in-licensing clinical drugs. The small but experienced management team has built a focused private psychiatry company with the most mature clinical psychiatry drug portfolio in Europe or maybe worldwide. Neuro3d uses a seamless integration of medicinal chemistry, pharmacology and clinical development to successfully select new drug candidates quickly and with a much lower attrition rate than industry standard.
| CONTACT INFORMATION | | |
Address:
Phone:
Fax:
Web:
Contact:
| 130 Rue de la Mer Rouge
Bat. La Fabrique BP42002
Mulhouse F-68058
France
+33 (0)389 36 91 70
+33 (0)389 36 91 78
http://www.neuro3d.fr
Lubor Gaal
+33 (0)389 36 91 77 |
| COMPANY FACTS | | |
| Founded: | Dec 2000 | | Founders: | Jean-Paul Macher, Jean-Jacques Bourguignon, Charles Woler | | CEO: | Charles Woler | | CTO or technical lead: | Cesare Mondadori | | CFO or finance director: | Julien Coste | | Head of Sales: | Lubor Gaal | | Head of Marketing: | Lubor Gaal |
| | Stage: | Growth | | Category: | Biotechnology & Healthcare | | Sector: | Biopharmaceuticals | | Employees: | 39 | | Profitability: | Pre-revenue | | Funding raised: | Yes | | Funding sought: | No | | Seeking Partnerships: | Yes |
| NON-EXECUTIVE BOARD MEMBERS | | |
Laurent Ganem, General Partner, APAX Partners
Denis Lucquin, General Partner, Sofinnova Partners
Johan Christenson, Partner, Health Cap
Patrick Zenner, Former CEO of Hoffman La Roche USA Inc
Ron Lindsay, Chief Scientific Officer and VP R&D , DIADEXUS Inc
| KEY CUSTOMERS | | |
| KEY BUSINESS PARTNERS | | |
| KEY COMPETITORS | | |
| CAPITAL RAISED | | |
To view this information you must be signed in and subscribed to the online dataservice, sign in here.
To read more about the Online data service click here |
| PUBLIC OFFERINGS | | |
| Date | Type | Exchange |
| No public offerings |
|
|
|
